Emerging drugs for the treatment of mucopolysaccharidoses.
2016
ABSTRACTIntroduction: Despite being reported for the first time almost one century ago, only in the last few decades effective have treatments become available for the mucopolysaccharidoses (MPSs), a group of 11 inherited metabolic diseases that affect lysosomal function. These diseases are progressive, usually severe, and, in a significant number of cases, involve cognitive impairment.Areas covered: This review will not cover established treatments such as bone marrow/hematopoietic stem cell transplantation and classic intravenous enzyme replacement therapy (ERT), whose long-term outcomes have already been published (MPS I, MPS II, and MPS VI), but it instead focuses on emerging therapies for MPSs. That includes intravenous ERT for MPS IVA and VII, intrathecal ERT, ERT with fusion proteins, substrate reduction therapy, gene therapy, and other novel approaches.Expert opinion: The available treatments have resulted in improvements for several disease manifestations, but they still do not represent a cure f...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
120
References
36
Citations
NaN
KQI